StockData

Sonoma Pharmaceuticals vs Utah Medical Products

SNOA and UTMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SNOA and UTMD compare

Utah Medical Products is the larger company, worth 55 times as much as Sonoma Pharmaceuticals ($230M against $4.2M).

Utah Medical Products pays a dividend yielding 1.7%; Sonoma Pharmaceuticals does not pay one.

Sonoma Pharmaceuticals scores higher on the StockData Score (11 against 10 for Utah Medical Products), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSNOAUTMD
Size and price
Market cap$4.2M$230M
Share price$0.880$72.36
Change, 1 year−75.1%29.0%
Change, 5 years−99.2%−39.9%
Beta (5Y)2.090.25
Employees250140
StockData Score
Total score11 (better)10
Valuation score33
Growth score3 (better)0
Performance score2 (better)1
Health score34 (better)
Dividend score02 (better)
Valuation
P/E–22.1×
P/S0.2× (better)6.4×
P/B0.6× (better)1.9×
EV/EBITDA–13.9×
P/FCF–20.1×
FCF yield−63.0%5.0% (better)
Fair value$4.67$75.74
Margin of safety81.2% (better)4.5%
Growth
Revenue growth (TTM)47.0%–
Revenue growth, 5Y average0.95% (better)−1.8%
EPS growth, 5Y average–3.4%
Profitability
Gross margin38.9%57.9% (better)
Operating margin−6.4%28.4% (better)
Net margin−10.3%–
FCF margin−12.1%31.7% (better)
Return on equity−42.5%–
Return on invested capital−112%23.9% (better)
Financial health
Debt / equity0.020.00 (better)
Net debt / EBITDA–−8.51
Current ratio2.9948.62 (better)
Altman Z-score−13.6757.44 (better)
Piotroski F-score3–
Dividends and buybacks
Dividend yield–1.7%
Buyback yield−94.0%0.80% (better)
Shareholder yield−94.0%2.5% (better)
Ownership
Held by institutions2.3%72.8%
Held by insiders11.1%7.3%
Insider net buying, 12 months–$66.8K
Short interest, % of float1.6%5.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.